Takeda's Rozerem To Launch In September Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Ramelteon clears FDA for "treatment of insomnia characterized by difficulty with sleep onset." Takeda is positioning Rozerem as the only prescription insomnia agent that does not carry controlled substance scheduling.